AI MARKET SCANNING

Zymeworks Inc

AVG HISTORICAL GAP -1.24%
MAX GAP RECORD -9.79%
🔒 PRO INSTITUTIONAL AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡

SENTINEL HISTORICAL GAP VIEWER

// $ZYME
📊 1-YEAR TIMELINE (GAPS PLOTTED) 🔮 SIMULATE SETUP 🔒
Bullish Opening Gap Bearish Opening Gap T-1 Close Baseline

CATALYSTS & GAP HISTORY

Aug 06, 2026 Earnings Release 2026-08-06 (AFTER CLOSE)
+4.19%
May 07, 2026 Earnings Release 2026-05-07 (AFTER CLOSE)
-1.47%
Mar 02, 2026 Earnings Release 2026-03-02 (BEFORE OPEN)
-3.18%
Nov 06, 2025 Earnings Release 2025-11-06 (AFTER CLOSE)
-4.97%
Aug 07, 2025 Earnings Release 2025-08-07 (AFTER CLOSE)
+2.30%
May 07, 2025 Earnings Release 2025-05-07 (AFTER CLOSE)
+0.00%
Mar 05, 2025 Earnings Release 2025-03-05 (AFTER CLOSE)
-5.61%
Oct 31, 2024 Earnings Release 2024-10-31 (AFTER CLOSE)
-6.79%

VOLATILITY & GAP BIAS

AVG GAP MOVE 4.5%
Bullish Gaps (6)
Bearish Gaps (8)
Neutral / Flat (0)

QUANTITATIVE LIVE RADAR BLOTTER

Algorithmic execution stream for $ZYME

EXECUTIONS0 LOGS
STATUS🔒 ENCRYPTED
Execution Date Strategy & Setup Direction Execution Range Hold Time Net PnL
Radar monitoring: awaiting next setup.
🔒 Real-Time Strategy Telemetry Protected

Exact execution levels, Trailing Stops, and live bot signals are reserved for PRO members.

UNLOCK LIVE RADAR ⚡

📖 Intelligence Summary

Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab's unique binding properties result in multiple mechanisms…

NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗